Why the study?
Although diabetes-related PAD has an accelerated course and worse outcomes than non-diabetic PAD, current medical treatment does not distinguish between them and provides standard antiplatelet and lipid-lowering drugs for all PAD patients.
Design
Review
Key result
Both smoking-related and diabetes-related peripheral artery disease exhibit increased thrombo-inflammatory responses, though the specific magnitude of thrombo-inflammation in diabetes compared with smokers remains unknown.
Authors
Loading...
May inform subtype-specific PAD strategies; leaves open direct thrombo-inflammatory comparisons between diabetes and smoking.
This review emphasizes the pathophysiological differences between diabetes- and smoking-related PAD, advocating for disease-specific therapeutic strategies rather than a one-size-fits-all approach.
Alnima et al. (2023) conducted a review in Peripheral artery disease. Both smoking-related and diabetes-related peripheral artery disease exhibit increased thrombo-inflammatory responses, though the specific magnitude of thrombo-inflammation in diabetes compared with smokers remains unknown.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: